Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

Phase 3 Completed 224 enrolled Yangtze River Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to evaluate the analgesic efficacy and safety of meloxicam injection in subjects with moderate-to-severe pain following abdominal surgery. The primary efficacy endpoint is the summed pain intensity difference over 24 hours ( SPID24)

Timeline

Start: 2024-01-29
Primary completion: 2024-11-20
Completion: 2025-02-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Meloxicam	Small molecule	30 mg	Intravenous

Indications

No indication recorded.